2021
DOI: 10.1007/s00262-021-02926-3
|View full text |Cite
|
Sign up to set email alerts
|

Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

8
69
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 58 publications
(78 citation statements)
references
References 46 publications
8
69
1
Order By: Relevance
“…Other previous studies showed that pretreatment LIPI was a prognostic biomarker in ED-SCLC patients receiving chemotherapy or LD-SCLC patients (37,38). In a recent retrospective study with data from a randomized clinical trial, inflammatory markers, including LIPI, were evaluated in ED-SCLC patients receiving atezolizumab and chemotherapy, and the results showed that LIPI was not an independent prognostic factor (39). However, their study had a small sample size and the patient population in the prospective clinical trial could not represent the entire SCLC population receiving first-line PD-1/ PD-L1 inhibitor treatment.…”
Section: Discussionmentioning
confidence: 98%
See 1 more Smart Citation
“…Other previous studies showed that pretreatment LIPI was a prognostic biomarker in ED-SCLC patients receiving chemotherapy or LD-SCLC patients (37,38). In a recent retrospective study with data from a randomized clinical trial, inflammatory markers, including LIPI, were evaluated in ED-SCLC patients receiving atezolizumab and chemotherapy, and the results showed that LIPI was not an independent prognostic factor (39). However, their study had a small sample size and the patient population in the prospective clinical trial could not represent the entire SCLC population receiving first-line PD-1/ PD-L1 inhibitor treatment.…”
Section: Discussionmentioning
confidence: 98%
“…To the best of our knowledge, this is the first study to demonstrate the relationship between pretreatment LIPI and the survival outcomes of SCLC patients receiving first-line ICI treatment. In previous studies, the included cohorts were divided into three groups (LIPI good, LIPI intermediate, and LIPI poor) (37)(38)(39). However, no obvious differences were reported between the LIPI intermediate and LIPI poor groups in terms of OS (37).…”
Section: Discussionmentioning
confidence: 99%
“…The correlation between systemic immune, cancer-related inflammation status and prognosis has been considered as an established fact (6). A variety of blood and biochemical parameters have been investigated as potential inflammatory biomarkers associated with drug efficacy and prognosis, including neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-tomonocyte ratio (LMR), cytokines, and lactate dehydrogenase (LDH) (13,(16)(17)(18)(19).…”
Section: Introductionmentioning
confidence: 99%
“…ALI was originally used to assess the prognosis of lung cancer patients, such as non-small cell lung cancer 28 and small cell lung cancer. 29 Soon after, researchers found that ALI is also a good independent prognostic indicator in nasopharyngeal carcinoma, 30 head and neck squamous cell carcinoma, 31 32 esophageal cancer, 32 gastric cancer, 21,33 colorectal cancer, 34,35 melanoma, 36 and diffuse large B-cell lymphoma. 37 ALI is an index related to inflammation and nutritional status.…”
mentioning
confidence: 99%